Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ:PCRX) has announced that it will release its second quarter 2024 financial results after U.S. markets close on Tuesday, July 30, 2024. The company will host a live conference call and webcast at 4:30 p.m. ET following the release. Interested participants can pre-register for the Q&A session via telephone, and all registrants will receive dial-in information and a PIN for call access. Additionally, a live audio webcast will be available through the 'Events' page on Pacira's investor website. For those unable to join the live call, a replay of the webcast will be accessible on the company's website for approximately two weeks after the event.

TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

FAQ

When will Pacira BioSciences (PCRX) report its Q2 2024 financial results?

Pacira BioSciences (PCRX) will report its second quarter 2024 financial results after the close of U.S. markets on Tuesday, July 30, 2024.

What time is Pacira's (PCRX) Q2 2024 earnings conference call scheduled for?

Pacira's (PCRX) Q2 2024 earnings conference call and webcast is scheduled for 4:30 p.m. ET on Tuesday, July 30, 2024, following the release of their financial results.

How can investors participate in Pacira's (PCRX) Q2 2024 earnings call?

Investors can participate in Pacira's (PCRX) Q2 2024 earnings call by pre-registering for the telephone Q&A session or by accessing the live webcast through the 'Events' page on Pacira's investor website.

Will there be a replay available for Pacira's (PCRX) Q2 2024 earnings call?

Yes, a replay of the webcast for Pacira's (PCRX) Q2 2024 earnings call will be available on the company's website for approximately two weeks following the live event.